La vendita allo scoperto per Oak Woods Acquisition Corporation - Right dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Oak Woods Acquisition Corporation - Right. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Oak Woods Acquisition Corporation - Right (NASDAQ:OAKUR) Azioni, Report sulle vendite allo scoperto

Oak Woods Acquisition Corporation - Right

Wells Fargo analyst Ken Gawrelski maintains Etsy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) with a Underweight and lowers the price target from $47 to $44.

News

Price Target

Analyst Ratings

ETSY

Wells Fargo Maintains Underweight on Etsy, Lowers Price Target to $44

WIIM

LECO

Lincoln Electric shares are trading higher after the company reported better-than-expected Q3 adjusted EPS results.

TD Cowen analyst Jeffrey Osborne maintains Aptiv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>) with a Buy and lowers the price target from $95 to $74.

APTV

TD Cowen Maintains Buy on Aptiv, Lowers Price Target to $74

Imperial Oil shares are trading lower after the company reported mixed Q3 financial results.

CTRA

Corterra Energy shares are trading lower after the company reported worse-than-expected Q3 adjusted EPS results and cut its FY24 capital expenditure.

B of A Securities analyst Bryan Spillane maintains Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) with a Neutral and lowers the price target from $100 to $75.

B of A Securities Maintains Neutral on Estee Lauder Cos, Lowers Price Target to $75

UBS analyst Jay Sole maintains Kontoor Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KTB#NYSE">KTB</a>) with a Buy and raises the price target from $103 to $110.

UBS Maintains Buy on Kontoor Brands, Raises Price Target to $110

Dayforce shares are trading higher after BMO Capital maintained an Outperform rating on the stock and raised its price target from $70 to $80.

Service Corp International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCI#NYSE">SCI</a>) reported better-than-expected third-quarter adjusted <a href="https://www.benzinga.com/quote/SCI/earnings">EPS results on Thursday</a>.
Service Corp Intl reported quarterly earnings of 79 cents per share beat the analyst consensus estimate of 77 cents per shsare. The company reported quarterly sales of $1.014 billion which missed the analyst consensus estimate of $1.016 billion.
Tom Ryan, the Company&#8217;s Chairman and CEO, commented, &#8220;Today we reported adjusted earnings per share of $0.79 and net cash provided by operating activities excluding special items of $269 million. We are excited to see the positive impact in funeral revenue from our new marketing agreement with our new preferred preneed insurance provider, which launched during the quarter. Additionally, we are pleased both funeral and cemetery gross profit were relatively stable versus the prior year third quarter with modest revenue growth reflecting our continued focus on managing fixed costs.&#8221;
Service Corp Intl said it sees fourth-quarter adjusted loss of $1.00-1.10 per share, versus estimates of 77 cents per share.
Service Corp International shares gained 0.2% to trade at $81.79 on Friday.
These analysts made changes to their price targets on Service Corp International following earnings announcement.
<ul>
<li>Raymond James analyst John Ransom maintained Service Corp Intl with an Outperform and increased the price target from $80 to $85.</li>
<li>Truist Securities analyst Tobey Sommer maintained the stock with a Buy and raised the price target from $84 to $92.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41685620/top-3-energy-stocks-that-are-preparing-to-pump-in-november">Top 3 Energy Stocks That Are Preparing To Pump In November</a></li>
</ul>

Earnings

Markets

Trading Ideas

Service Corp International Analysts Boost Their Forecasts After Upbeat Earnings

TD Cowen analyst Jeffrey Osborne maintains Generac Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNRC#NYSE">GNRC</a>) with a Buy and raises the price target from $172 to $183.

GNRC

TD Cowen Maintains Buy on Generac Hldgs, Raises Price Target to $183

UBS analyst Eliana Merle maintains Madrigal Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGL#NASDAQ">MDGL</a>) with a Buy and raises the price target from $411 to $441.

MDGL

UBS Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $441

TD Cowen analyst Jeffrey Osborne maintains Itron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRI#NASDAQ">ITRI</a>) with a Buy and raises the price target from $125 to $136.

ITRI

TD Cowen Maintains Buy on Itron, Raises Price Target to $136

Craig-Hallum analyst Anthony Stoss maintains Silicon Motion Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIMO#NASDAQ">SIMO</a>) with a Buy and lowers the price target from $96 to $90.

SIMO

Craig-Hallum Maintains Buy on Silicon Motion Technology, Lowers Price Target to $90

On Thursday,&nbsp;Bristol Myers Squibb &amp; Co&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)&nbsp;posted third-quarter revenues of $11.89 billion, beating the consensus of $11.28 billion, an increase of 8% year-over-year, or 10% when adjusted for foreign exchange impacts, primarily driven by the&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41655052/bristol-myers-squibb-boosts-2024-outlook-on-strong-demand-for-blood-thinner-med-new-drugs-drive-q" rel="noreferrer noopener">Growth Portfolio and&nbsp;Eliquis</a>.
Growth Portfolio worldwide revenues increased to $5.81 billion compared to $4.95&nbsp;billion a year ago, representing growth of 18% on a reported basis or 20% when adjusted for&nbsp;foreign exchange impacts.
BMO Capital Markets appreciates a conservative approach in the neuropsych space, though it notes management&#8217;s reserved stance on revenue expectations. It highlights that significant revenue is not expected until the second half of 2025, with a gradual launch anticipated for schizophrenia treatment.
The analyst considers the potential for Alzheimer&#8217;s psychosis treatment as an added upside, likely to positively impact sentiment.
While Bristol-Myers Squibb&#8217;s recent quarterly performance showed encouraging progress in top-line growth and cost management, its true transformation will stem from its pipeline, the BMO analyst writes.
The recent approval of Cobenfy, along with newly launched growth products, could bring the momentum investors have been anticipating.
Truist analysts noted that much of the Q3 earnings call centered on KarXT (Cobenfy), a critical asset for treating schizophrenia that could drive significant revenue and support long-term growth.
Truist analyst projects global peak sales at $4.2 billion, below the $5.4 billion consensus estimate.
While business development and partnerships are crucial to diversifying the company&#8217;s portfolio and strengthening its long-term outlook, Truist emphasized that maintaining dividends and reducing debt remain top priorities.
Price Action: BMY stock is down 1.91% at $54.71 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41686173/cancer-focused-essa-pharma-ends-prostate-cancer-trial-due-to-insufficient-efficacy-from-combinati" target="_blank" rel="noreferrer noopener">Cancer-Focused ESSA Pharma Ends Prostate Cancer Trial Due to Insufficient Efficacy From Combination Therapy</a></li>
</ul>
Image: Wikimedia Commons

Analyst Color

Biotech

Large Cap

Health Care

General

Bristol Myers Squibb Expects New Schizophrenia Treatment To Boost Long-Term Growth, Analysts Remain Cautious

Shares of Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) are trading lower Friday amid <a href="https://www.benzinga.com/markets/equities/24/11/41677355/trump-loses-1-9b-in-net-worth-as-djt-stock-tumbles-2nd-time-this-week">continued volatility</a> leading up to the 2024 U.S. presidential election.
What To Know: With the US elections approaching, Trump Media &amp; Technology Group's stock is experiencing volatility as it is closely tied to news about former President Trump and his prospects of winning.
According to S3 Partners, DJT shares surged in October as a short squeeze forced short sellers to cover positions. S3 predicts DJT could climb to $60 if Trump wins the election, but warns it could become "worthless" if he loses. Trading in DJT has been halted several times amid rapid price movements related to election developments.
What Else: <a href="https://nypost.com/2024/11/01/business/truth-social-stock-boom-fueled-by-chatter-of-possible-sale-to-elon-musk/">Commentary from the New York Post</a> this morning speculated Elon Musk may be considering a merger or acquisition of Truth Social through X (formerly Twitter). The Post has not confirmed this speculation. 
DJT Price Action: Trump Media and Technology shares were down 11.3% at $31.34 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="530" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01132722/DJT-1024x530.png" alt="" class="wp-image-626033" style="width:519px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01132722/DJT-1024x530.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01132722/DJT-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01132722/DJT-768x397.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01132722/DJT.png 1480w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/startups/24/11/41691861/im-not-kidding-reddit-was-amazing-jim-cramer-compares-reddit-to-google-saying-choosing-between-them">&#8216;I&#8217;m Not Kidding, Reddit Was Amazing&#8217; — Jim Cramer Compares Reddit To Google, Saying Choosing Between Them Isn&#8217;t Easy</a></li>
</ul>
Image via Wikimedia Commons.

Movers

Trump Media & Technology Shares Are Dipping Today: What's Going On

UBS analyst Stephen Ju maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Buy and raises the price target from $223 to $230.

AMZN

UBS Maintains Buy on Amazon.com, Raises Price Target to $230

TD Cowen analyst Moshe Orenbuch maintains Credit Acceptance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CACC#NASDAQ">CACC</a>) with a Sell and lowers the price target from $400 to $380.

CACC

TD Cowen Maintains Sell on Credit Acceptance, Lowers Price Target to $380

Roth MKM analyst Scott Stember maintains Fox Factory Hldg (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXF#NASDAQ">FOXF</a>) with a Neutral and lowers the price target from $45 to $36.

FOXF

Roth MKM Maintains Neutral on Fox Factory Hldg, Lowers Price Target to $36

Roth MKM analyst Chip Moore maintains Itron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRI#NASDAQ">ITRI</a>) with a Buy and raises the price target from $125 to $130.

Roth MKM Maintains Buy on Itron, Raises Price Target to $130

<a href="https://www.bloomberg.com/news/articles/2024-11-01/chevron-flags-possible-us-job-cuts-in-3-billion-cost-cutting" title="https://www.bloomberg.com/news/articles/2024-11-01/chevron-flags-possible-us-job-cuts-in-3-billion-cost-cutting">https://www.bloomberg.com/news/articles/2024-11-01/chevron-flags-possible-us-job-cuts-in-3-billion-cost-cutting</a>

Comments

Oak Woods Acquisition Corporation - Right

Vendite allo scoperto

Oak Woods Acquisition Corporation - Right (NASDAQ:OAKUR) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO